Comparative Pharmacology
Head-to-head clinical analysis: NYSTATIN AND TRIAMCINOLONE ACETONIDE versus STERI STAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NYSTATIN AND TRIAMCINOLONE ACETONIDE versus STERI STAT.
NYSTATIN AND TRIAMCINOLONE ACETONIDE vs STERI-STAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nystatin binds to ergosterol in fungal cell membranes, forming pores that cause leakage of intracellular contents and cell death. Triamcinolone acetonide is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation, immune response, and vasodilation.
Binds to the 50S ribosomal subunit of bacteria, inhibiting protein synthesis by blocking peptide bond formation and translocation.
Apply thin layer to affected area twice daily for 2-4 weeks. Topical only.
Adults: 1 gram intravenously every 8 hours infused over 60 minutes.
None Documented
None Documented
Nystatin: not systemically absorbed; terminal half-life not applicable. Triamcinolone acetonide: after intramuscular injection, terminal half-life is approximately 2-5 hours; after topical application, minimal systemic absorption precludes meaningful half-life determination.
Terminal elimination half-life is 8-12 hours in adults with normal renal function; prolonged to 18-24 hours in moderate renal impairment (CrCl 30-50 mL/min).
Nystatin: primarily excreted unchanged in feces via bile (>90%); negligible renal excretion (<1%). Triamcinolone acetonide: primarily hepatically metabolized; conjugated metabolites excreted renally (70%) and via bile (20% fecal). Systemic absorption of triamcinolone acetonide after topical application is minimal (<1%).
Renal excretion of unchanged drug accounts for approximately 95% of elimination; biliary/fecal elimination is minimal (<5%).
Category D/X
Category C
Corticosteroid
Corticosteroid